Using a virus to deliver the genetic tool worked better than other methods, with about 80% of liver cancer cells taking up the treatment successfully.

Scientific Claim

Lentivirus-mediated siRNA delivery achieved approximately 80% infection efficiency in Hep3B and HCCLM3 human hepatocellular carcinoma cell lines, which was higher than liposome-based transfection methods used in previous tests.

Original Statement

“Our results showed that the rate of lentivirus-mediated siRNA infection reached 80% which is much higher than that of liposome transfection we once used in our pretest.”

From study:Unknown Title

Evidence Quality Assessment

Claim Status

appropriately stated

Study Design Support

Design supports claim

Appropriate Language Strength

definitive

Can make definitive causal claims

Assessment Explanation

The study directly measured infection efficiency in cell cultures and compared it to previous liposome methods. The claim accurately reports the observed efficiency without overgeneralizing.

Evidence from Studies

Supporting (1)

Unknown Title

Cross-Sectional Study

In Vitro

Contradicting (0)

No contradicting evidence found

Source Study

Unknown Title

DOI: 10.1155/2015/490681

Similar Assertions

Using a virus to deliver the genetic tool worked better than other methods, with about 80% of liver cancer cells taking up the treatment successfully.

93%

Using a special virus to deliver a genetic tool that blocks ER-α gene activity successfully lowered ER-α levels in liver cancer cells within a day or two.

83%

When using a control that doesn't block ER-α, there was no change in cancer cell growth, invasion, or death compared to normal cells.

73%